Uniqure (NASDAQ:QURE) had its price objective raised by HC Wainwright from $42.00 to $48.00 in a research note released on Monday morning, Marketbeat Ratings reports. They currently have a buy rating on the biotechnology company’s stock.
“Our new $48 price target, is based on a 13-year DCF analysis that incorporates rNPV of two pipeline products, including: (1) Hemophilia B at a 70% POS driven by company’s clinical update as of September 23, 2018, vs. prior 65%; and (2) 5% POS. We anticipate Hemophilia B commercial launch during 2021 and model risk-adjusted peak sales of roughly $981M, upped from $820M previously, during 2028. We assume a launch price of $772.5K (durability >5 years), and at peak, we estimate about 775 patients in the U.S. and approximately 1,050 patients in the developed markets who would have received uniQure’s gene therapy, which represents a 50% of the overall commercial opportunity.”,” the firm’s analyst commented.
Several other equities analysts also recently weighed in on the stock. Cantor Fitzgerald set a $58.00 price target on shares of Uniqure and gave the company a buy rating in a report on Thursday, August 23rd. Cowen reaffirmed a buy rating on shares of Uniqure in a report on Monday, August 13th. BidaskClub raised shares of Uniqure from a buy rating to a strong-buy rating in a report on Thursday, August 9th. Janney Montgomery Scott reaffirmed a buy rating on shares of Uniqure in a report on Wednesday, August 8th. Finally, Zacks Investment Research downgraded shares of Uniqure from a strong-buy rating to a hold rating in a report on Wednesday, July 25th. Two analysts have rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the stock. The company has an average rating of Buy and an average target price of $45.56.
Uniqure (NASDAQ:QURE) last issued its quarterly earnings results on Wednesday, August 8th. The biotechnology company reported ($0.57) earnings per share for the quarter, beating the consensus estimate of ($0.61) by $0.04. Uniqure had a negative net margin of 677.98% and a negative return on equity of 72.12%. The business had revenue of $3.05 million for the quarter, compared to the consensus estimate of $3.37 million. equities analysts expect that Uniqure will post -2.44 earnings per share for the current fiscal year.
Several hedge funds have recently added to or reduced their stakes in QURE. OppenheimerFunds Inc. purchased a new position in shares of Uniqure in the second quarter worth $63,553,000. Redmile Group LLC purchased a new position in shares of Uniqure in the second quarter worth $61,402,000. Millennium Management LLC lifted its holdings in shares of Uniqure by 242.8% in the first quarter. Millennium Management LLC now owns 759,585 shares of the biotechnology company’s stock worth $17,850,000 after buying an additional 538,031 shares in the last quarter. FMR LLC lifted its holdings in shares of Uniqure by 16.6% in the second quarter. FMR LLC now owns 3,694,681 shares of the biotechnology company’s stock worth $139,659,000 after buying an additional 526,283 shares in the last quarter. Finally, Eventide Asset Management LLC purchased a new position in shares of Uniqure in the first quarter worth $7,873,000. 59.32% of the stock is currently owned by hedge funds and other institutional investors.
Uniqure Company Profile
uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company develops AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia; and AMT-126, a gene therapy for the treatment of congestive heart failure and AMT-130 to treat huntington's disease.
Featured Article: Average Daily Trade Volume Explained
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.